Cooper Companies (NASDAQ:COO) Downgraded to “Hold” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Cooper Companies (NASDAQ:COO) from a buy rating to a hold rating in a research note released on Saturday morning,Wall Street Zen reports.

A number of other analysts have also recently weighed in on the stock. Piper Sandler cut shares of Cooper Companies from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $86.00 to $59.00 in a report on Thursday. Weiss Ratings reiterated a “sell (d)” rating on shares of Cooper Companies in a research note on Friday, September 4th. Wells Fargo & Company set a $61.00 target price on shares of Cooper Companies and gave the company an “equal weight” rating in a research report on Thursday. Stifel Nicolaus set a $70.00 target price on shares of Cooper Companies and gave the company a “buy” rating in a research note on Thursday. Finally, Citigroup reaffirmed a “neutral” rating and issued a $60.00 price target (down from $80.00) on shares of Cooper Companies in a report on Thursday. Five equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $71.47.

Cooper Companies Trading Down 0.5%

Shares of NASDAQ COO opened at $53.91 on Friday. Cooper Companies has a 1-year low of $51.01 and a 1-year high of $89.83. The business has a fifty day moving average price of $71.62 and a 200 day moving average price of $69.70. The stock has a market capitalization of $10.25 billion, a P/E ratio of 18.40, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.22 and a quick ratio of 0.78.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.03. The company had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.10 billion. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.The firm’s quarterly revenue was up .5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Equities research analysts expect that Cooper Companies will post 4.53 EPS for the current fiscal year.

Cooper Companies declared that its Board of Directors has approved a stock buyback plan on Wednesday, September 9th that authorizes the company to repurchase $3.00 billion in shares. This repurchase authorization authorizes the medical device company to repurchase up to 22.7% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

Institutional Trading of Cooper Companies

A number of institutional investors have recently bought and sold shares of COO. Root Financial Partners LLC lifted its stake in shares of Cooper Companies by 104.5% during the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after buying an additional 162 shares during the period. Avalon Trust Co acquired a new position in shares of Cooper Companies in the 2nd quarter valued at $25,000. SJS Investment Consulting Inc. raised its stake in Cooper Companies by 107.5% in the 1st quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock worth $26,000 after acquiring an additional 187 shares during the last quarter. Elevation Wealth Partners LLC raised its stake in Cooper Companies by 1,136.4% in the 2nd quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock worth $29,000 after acquiring an additional 375 shares during the last quarter. Finally, Continuum Advisory LLC acquired a new stake in Cooper Companies during the 2nd quarter worth about $30,000. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper reported adjusted fiscal Q3 earnings of $1.15 per share, ahead of the approximately $1.11–$1.12 consensus, with earnings up from $0.49 a year earlier. Cost controls and continued fertility-related growth helped offset weakness elsewhere. Cooper Companies Bets on Fertility Growth Despite Weakness in CooperVision
• Positive Sentiment: The board authorized an additional $1 billion of repurchases, bringing the total buyback authorization to $3 billion. The program could support per-share earnings and signal management believes COO shares are undervalued. Cooper Outlines Q4 EPS and Adds to Buyback Authorization
• Neutral Sentiment: Cooper completed a strategic review but chose not to pursue a sale or separate transaction for CooperSurgical. Keeping the business preserves its fertility-growth opportunity, but investors had apparently anticipated a potential deal or value-unlocking action. Cooper Cos. Stock Drops After Soft Outlook and No Deal
• Negative Sentiment: Revenue rose only about 1% to $1.066 billion, missing the roughly $1.10 billion consensus. U.S. channel destocking and inventory reductions pressured CooperVision, raising concerns about near-term demand and sales momentum. COO Q3 Earnings Top Estimates, Revenues Miss on Destocking
• Negative Sentiment: Management reduced fiscal 2026 earnings guidance to $4.51–$4.55 per share and issued fourth-quarter guidance of $1.05–$1.09, below prior expectations. The weaker outlook triggered multiple analyst downgrades and price-target cuts, including from Baird, UBS, JPMorgan and William Blair.
• Negative Sentiment: Law firms have announced securities-fraud investigations connected with the post-earnings decline. These notices are often promotional, but they add to negative investor sentiment and potential legal uncertainty. Securities Fraud Investigation Into Cooper Companies Announced

About Cooper Companies

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.